Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track PULM with free AI briefings, catalyst countdowns, and dilution alerts.

PULM · Pulmatrix, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$2.2M Cash on Hand
6mo Cash Runway
Follow PULM by email Get an email when PULM reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about PULM, unsubscribe in one click. Privacy

📣 What PULM Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Itraconazole Powder ABPA Phase 2 · NCT05667662 Terminated
RUT058-60 Postoperative Wound Infection-deep Phase 1/2 · NCT02280395 Terminated
Sodium Lauryl Sulfate Irritation/Irritant Phase 1 · NCT02198963 Completed
Active Comparator: 6.0mg GRI-0621 Chronic Obstructive Pulmonary Disease (COPD) Phase 1 · NCT01921712 Completed
Dihydroergotamine Healthy Phase 1 · NCT05351086 Completed
PUR003 Healthy Phase 1 · NCT00947687 Completed
PUR0200 Healthy Phase 1 · NCT02671825 Completed
PUR118 Cystic Fibrosis Phase 1 · NCT01543191 Completed
PUR1800 250 ug Chronic Obstructive Pulmonary Disease (COPD) Phase 1 · NCT04759807 Completed
PUR3100 Healthy Phase 1 · NCT05351086 Completed
Reference Product Healthy Phase 1 · NCT02671825 Completed

Also used in these trials (approved or third-party drugs, not PULM's own candidates): Hypochlorous Acid, Itraconazole.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

PULM holds $2.2M in cash and short-term investments (as of Jun 30, 2026) and burns about $1.1M/quarter from operations, an estimated runway of 6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 80 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PULM files for a raise →

👥 Who Owns PULM

Insiders Form 4 data not loaded yet Other 5%+ holders 11.1% Institutions (14 holders) 9% Public and other holders 79.9%
HolderTypeShares% of sharesAs of
RCM Eos PIPE HOLDINGS, LLC 5%+ holder (13D) 405,358 11.10% 2026-04-16

Share count 3,652,285 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full PULM picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PULM and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.